{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:35:10Z","timestamp":1787603710403,"version":"build-2736575974"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bpg.2020.101689","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T20:34:28Z","timestamp":1601066068000},"page":"101689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Post liver transplant recurrent and de novo viral infections"],"prefix":"10.1016","volume":"46-47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4189-690X","authenticated-orcid":false,"given":"Dinesh","family":"Jothimani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-0294","authenticated-orcid":false,"given":"Mukul","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MOT.0000000000000392","article-title":"Liver transplantation around the world","volume":"22","author":"Trotter","year":"2017","journal-title":"Curr Opin Organ Transplant"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J\u00a0Viral Hepat"},{"issue":"34","key":"10.1016\/j.bpg.2020.101689_bib3","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1016\/j.bpg.2020.101689_bib5","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation","volume":"35","author":"Garcia-Retortillo","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jhep.2004.06.029","article-title":"Fibrosis progression after liver transplantation in patients with recurrent hepatitis C","volume":"41","author":"Neumann","year":"2004","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4065\/78.2.197","article-title":"Recent advances in liver transplantation","volume":"78","author":"Wiesner","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"4 Pt 1","key":"10.1016\/j.bpg.2020.101689_bib10","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1053\/jhep.2000.17924","article-title":"Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation","volume":"32","author":"Berenguer","year":"2000","journal-title":"Hepatology"},{"issue":"4 Pt 1","key":"10.1016\/j.bpg.2020.101689_bib11","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1053\/jhep.2000.17924","article-title":"Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation","volume":"32","author":"Berenguer","year":"2000","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib12","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2011.12.031","article-title":"Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy","volume":"56","author":"Berenguer","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.21090","article-title":"Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation","volume":"43","author":"Blasco","year":"2006","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.bpg.2020.101689_bib14","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3748\/wjg.v21.i13.3912","article-title":"Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation","volume":"21","author":"Gitto","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2020.101689_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2893.2007.00920.x","article-title":"Risk factors for hepatitis C recurrence after liver transplantation","volume":"14","author":"Roche","year":"2007","journal-title":"J\u00a0Viral Hepat"},{"issue":"Suppl 2","key":"10.1016\/j.bpg.2020.101689_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-2004-832932","article-title":"Natural history and management of hepatitis C infection after liver transplantation","volume":"24","author":"Charlton","year":"2004","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jhep.2011.06.031","article-title":"Immunosuppression and HCV recurrence after liver transplantation","volume":"56","author":"Samonakis","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2006.01.005","article-title":"Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression","volume":"44","author":"Berenguer","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.bpg.2020.101689_bib19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/lt.21182","article-title":"Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study","volume":"13","author":"Klintmalm","year":"2007","journal-title":"Liver Transplant"},{"issue":"10","key":"10.1016\/j.bpg.2020.101689_bib20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/01.TP.0000140881.07208.4E","article-title":"Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab\u00a0+ steroids or basiliximab\u00a0+ placebo, in addition to cyclosporine and azathioprine","volume":"78","author":"Filipponi","year":"2004","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.bpg.2020.101689_bib21","article-title":"Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/lt.20583","article-title":"Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome","volume":"12","author":"Watt","year":"2006","journal-title":"Liver Transplant"},{"issue":"11","key":"10.1016\/j.bpg.2020.101689_bib23","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/lt.22168","article-title":"Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts","volume":"16","author":"Tao","year":"2010","journal-title":"Liver Transplant"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study","volume":"55","author":"Foucher","year":"2006","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/lt.24383","article-title":"Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation","volume":"22","author":"Carrion","year":"2016","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2020.101689_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jvh.12534","article-title":"Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy","volume":"23","author":"Bunchorntavakul","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000456586","article-title":"Pre- and post-transplant treatment of viral hepatitis C","volume":"35","author":"Mutimer","year":"2017","journal-title":"Dig Dis"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib30","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib32","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib33","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib34","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.28923","article-title":"Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy","volume":"65","author":"Flemming","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2020.101689_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12664-012-0254-5","article-title":"A\u00a0new era in the treatment of chronic hepatitis C infection","volume":"32","author":"Jothimani","year":"2012","journal-title":"Indian J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib37","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12072-016-9744-3","article-title":"Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review","volume":"10","author":"Jothimani","year":"2016","journal-title":"Hepatol Int."},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"SOLAR-1 investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.bpg.2020.101689_bib39","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3748\/wjg.v22.i9.2844","article-title":"Hepatic decompensation\/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus","volume":"22","author":"Patel","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.bpg.2020.101689_bib41","first-page":"225A","article-title":"Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program","volume":"62","author":"Welzel","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/lt.24416","article-title":"Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection","volume":"22","author":"Fontana","year":"2016","journal-title":"Liver Transplant"},{"issue":"27","key":"10.1016\/j.bpg.2020.101689_bib43","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"ASTRAL-1 investigators. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.510290122","article-title":"High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes","volume":"29","author":"Prieto","year":"1999","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.bpg.2020.101689_bib45","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/00007890-199805150-00006","article-title":"Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury","volume":"65","author":"Rosen","year":"1998","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.bpg.2020.101689_bib46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/lt.21747","article-title":"Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation","volume":"15","author":"Shackel","year":"2009","journal-title":"Liver Transplant"},{"issue":"11","key":"10.1016\/j.bpg.2020.101689_bib47","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/jlts.2003.50252","article-title":"The use of hepatitis C-infected grafts in liver transplantation","volume":"9","author":"Arenas","year":"2003","journal-title":"Liver Transplant"},{"issue":"10","key":"10.1016\/j.bpg.2020.101689_bib48","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/lt.20849","article-title":"Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts","volume":"12","author":"Khapra","year":"2006","journal-title":"Liver Transplant"},{"issue":"11","key":"10.1016\/j.bpg.2020.101689_bib49","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/TP.0b013e318219eb8f","article-title":"Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study","volume":"91","author":"Ballarin","year":"2011","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib50","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.transproceed.2012.05.012","article-title":"Liver transplantation from anti-hepatitis C virus-positive donors: our experience","volume":"44","author":"\u00c1lvaro","year":"2012","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.bpg.2020.101689_bib51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.bpg.2020.101689_bib52","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.dld.2014.06.004","article-title":"Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late","volume":"46","author":"Pellicelli","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib53","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.bpg.2020.101689_bib54","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/lt.21322","article-title":"Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study","volume":"13","author":"McCashland","year":"2007","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2020.101689_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0168-8278(92)90138-F","article-title":"Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications","volume":"14","author":"O\u2019Grady","year":"1992","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib56","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.1840130402","article-title":"Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease","volume":"13","author":"Todo","year":"1991","journal-title":"Hepatology"},{"issue":"25","key":"10.1016\/j.bpg.2020.101689_bib57","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen","volume":"329","author":"Samuel","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib58","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.gastro.2007.01.005","article-title":"Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation","volume":"132","author":"Gane","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib59","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/tid.12434","article-title":"Tenofovir\/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients","volume":"17","author":"Fern\u00e1ndez","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib60","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1399-3062.2012.00741.x","article-title":"Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation","volume":"14","author":"Cholongitas","year":"2012","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib61","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/lt.23628","article-title":"Randomized trial of emtricitabine\/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation","volume":"19","author":"Teperman","year":"2013","journal-title":"Liver Transplant"},{"issue":"9","key":"10.1016\/j.bpg.2020.101689_bib62","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/lt.23692","article-title":"Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis","volume":"19","author":"Wadhawan","year":"2013","journal-title":"Liver Transplant"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib63","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cgh.2019.05.057","article-title":"Potential benefits of switching liver transplant recipients to tenofovir alafenamide prophylaxis","volume":"18","author":"Sripongpun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib64","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/lt.21998","article-title":"Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review","volume":"16","author":"Saab","year":"2010","journal-title":"Liver Transplant"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4174\/astr.2015.89.3.145","article-title":"De novo hepatitis B virus infection developing after liver transplantation using a graft positive for hepatitis B core antibody","volume":"89","author":"Han","year":"2015","journal-title":"Ann Surg Treat Res"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib66","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/jlts.2001.23911","article-title":"Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy","volume":"7","author":"Yu","year":"2001","journal-title":"Liver Transplant"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib67","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007890-200202150-00027","article-title":"Failure of reactivation of hepatitis B after liver transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients","volume":"73","author":"Maguire","year":"2002","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2011.06.016","article-title":"Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation","volume":"56","author":"Mederacke","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"7798","key":"10.1016\/j.bpg.2020.101689_bib69","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A\u00a0pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bpg.2020.101689_bib70","unstructured":"Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus10.1002\/jmv.25688. Epub.2020 Feb 7. PMID: 31994738; PMCID: PMC7166400."},{"key":"10.1016\/j.bpg.2020.101689_bib71","author":"World Health Organization"},{"key":"10.1016\/j.bpg.2020.101689_bib72","series-title":"Evaluating new evidence in the early dynamics of the novel coronavirus COVID-19 outbreak inWuhan, China with real time domestic traffic and potential asymptomatic transmissions","author":"Zhou","year":"2020"},{"key":"10.1016\/j.bpg.2020.101689_bib73","article-title":"Specific ACE2 expression in cholangiocytes may CauseLiver damage after 2019-nCoV infection","author":"Chai","year":"2020","journal-title":"BioRxiv Feb"},{"key":"10.1016\/j.bpg.2020.101689_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.06.006","article-title":"COVID-19 and the liver","author":"Jothimani","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.bpg.2020.101689_bib75","article-title":"High rates of 30-day mortality in patients with cirrhosis and COVID-19","author":"Iavarone","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.bpg.2020.101689_bib76","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-020-10092-4","article-title":"COVID-19 in Decompensated cirrhosis","author":"Rela","year":"2020","journal-title":"Hepatology International"},{"key":"10.1016\/j.bpg.2020.101689_bib77","first-page":"1","article-title":"Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) [published online ahead of print, 2020 Jul 4]","author":"Sarin","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.bpg.2020.101689_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/tri.13680","article-title":"Impact of COVID-19 on liver transplantation in europe: alert from an early survey of European liver and intestine transplantation association and European liver transplant registry","author":"Polak","year":"2020","journal-title":"Transpl Int"},{"issue":"7","key":"10.1016\/j.bpg.2020.101689_bib79","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/ajt.15941","article-title":"COVID-19 in solid organ transplant recipients: initial report from the US epicenter","volume":"20","author":"Pereira","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2020.101689_bib80","author":"Donato","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2020.101689_bib81","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1136\/gutjnl-2020-321923","article-title":"COVID-19 in an international European liver transplant recipient cohort","volume":"69","author":"Becchetti","year":"2020","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib82","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S2468-1253(20)30116-3","article-title":"COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy","volume":"5","author":"Bhoori","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2020.101689_bib83","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2468-1253(20)30125-4","article-title":"Determining risk factors for mortality in liver transplant patients with COVID-19","volume":"5","author":"Webb","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10236","key":"10.1016\/j.bpg.2020.101689_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2015.10.048","article-title":"Chronic infection with camelid hepatitis E virus in a liver transplant recipient who regularly consumes camel meat and milk","volume":"150","author":"Lee","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2020.101689_bib86","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/JCM.40.1.117-122.2002","article-title":"Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries","volume":"40","author":"Meng","year":"2002","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.bpg.2020.101689_bib87","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12879-015-1103-9","article-title":"Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States","volume":"15","author":"Koning","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.bpg.2020.101689_bib88","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa0706992","article-title":"Hepatitis E virus and chronic hepatitis in organ-transplant recipients","volume":"358","author":"Kamar","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.bpg.2020.101689_bib89","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1399-3046.2012.01740.x","article-title":"Prevalence of hepatitis E virus infection in pediatric solid organ transplant recipients--a single-center experience","volume":"16","author":"Hoerning","year":"2012","journal-title":"Pediatr Transplant"},{"issue":"10","key":"10.1016\/j.bpg.2020.101689_bib90","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/lt.21819","article-title":"Prevalence of hepatitis E virus infection in liver transplant recipients","volume":"15","author":"Haagsma","year":"2009","journal-title":"Liver Transplant"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib91","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3201\/eid1701.100527","article-title":"Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France","volume":"17","author":"Legrand-Abravanel","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib92","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cld.2014.05.002","article-title":"Hepatitis viruses and liver transplantation: evolving trends in antiviral management","volume":"18","author":"Verna","year":"2014","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib93","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2011.06.021","article-title":"Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient","volume":"56","author":"Schlosser","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib94","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","article-title":"Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants","volume":"140","author":"Kamar","year":"2011","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.bpg.2020.101689_bib95","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"370","author":"Kamar","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib96","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.gastro.2015.09.011","article-title":"Sofosbuvir inhibits hepatitis E virus replication in\u00a0vitro and results in an additive effect when combined with ribavirin","volume":"150","author":"Dao Thi","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib97","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2020.05.020","article-title":"Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - the HepNet SofE pilot study","volume":"73","author":"Cornberg","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib98","first-page":"77","article-title":"11th annual meeting of the IHMF (international herpes management forum). Management of CMV infection and disease in transplant patients. 27-29 february 2004","volume":"11","author":"Razonable","year":"2004","journal-title":"Herpesviridae"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib99","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: liver transplantation","volume":"64","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"9093","key":"10.1016\/j.bpg.2020.101689_bib100","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bpg.2020.101689_bib101","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1086\/375194","article-title":"Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir","volume":"187","author":"Razonable","year":"2003","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib102","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/lt.20417","article-title":"Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?","volume":"11","author":"Singh","year":"2005","journal-title":"Liver Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib103","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/160.5.752","article-title":"Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations","volume":"160","author":"Paya","year":"1989","journal-title":"J\u00a0Infect Dis"},{"issue":"39\u201340","key":"10.1016\/j.bpg.2020.101689_bib104","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4414\/smw.2005.10984","article-title":"Infections and allograft rejection - intertwined complications of organ transplantation","volume":"135","author":"Razonable","year":"2005","journal-title":"Swiss Med Wkly"},{"issue":"8606","key":"10.1016\/j.bpg.2020.101689_bib105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0140-6736(88)92356-2","article-title":"Cytomegalovirus infection and donor\/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation","volume":"2","author":"O\u2019Grady","year":"1988","journal-title":"Lancet"},{"issue":"1 Pt 2","key":"10.1016\/j.bpg.2020.101689_bib106","first-page":"1448","article-title":"Severe ductopenic rejection with features of vanishing bile duct syndrome: clinical, biochemical, and histologic evidence for spontaneous resolution","volume":"23","author":"Noack","year":"1991","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib107","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/jlts.2001.22040","article-title":"Hepatic artery thrombosis after orthotopic liver transplantation: a review of nonsurgical causes","volume":"7","author":"Pastacaldi","year":"2001","journal-title":"Liver Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib108","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1600-6143.2005.00797.x","article-title":"Valganciclovir Solid Organ Transplant Study Group. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+\/R- transplant recipients","volume":"5","author":"Humar","year":"2005","journal-title":"Am J Transplant"},{"issue":"Suppl 4","key":"10.1016\/j.bpg.2020.101689_bib109","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib110","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1600-6143.2004.00391.x","article-title":"Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+\/R- solid organ transplant recipients","volume":"4","author":"Humar","year":"2004","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib111","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.trim.2010.06.013","article-title":"Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients","volume":"23","author":"Sun","year":"2010","journal-title":"Transpl Immunol"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib112","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1179\/2047773213Y.0000000114","article-title":"Human cytomegalovirus detection by real-time PCR and pp65-antigen test in hematopoietic stem cell transplant recipients: a challenge in low and middle-income countries","volume":"107","author":"Breda","year":"2013","journal-title":"Pathog Glob Health"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib113","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The transplantation society international CMV consensus group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"14","key":"10.1016\/j.bpg.2020.101689_bib114","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial","volume":"323","author":"Singh","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/tri.12101","article-title":"Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients","volume":"26","author":"Onor","year":"2013","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib116","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jceh.2017.05.011","article-title":"Cytomegalovirus infection in liver transplant recipients: current approach to diagnosis and management","volume":"7","author":"Yadav","year":"2017","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.bpg.2020.101689_bib117","series-title":"Kucers\u2019 the Use of antibiotics: a clinical Review of antibacterial, antifungal, antiparasitic, and antiviral drugs; three volume set","author":"Grayson","year":"2017"},{"issue":"8","key":"10.1016\/j.bpg.2020.101689_bib118","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/10898540-000000000-00000","article-title":"New developments in the management of cytomegalovirus infection after solid organ transplantation","volume":"70","author":"Eid","year":"2010","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib119","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/femsre\/fuy004","article-title":"The human cytomegalovirus terminase complex as an antiviral target: a close-up view","volume":"42","author":"Ligat","year":"2018","journal-title":"FEMS Microbiol Rev"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib120","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib121","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/TP.0b013e318200b9f0","article-title":"Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients","volume":"91","author":"Boillat Blanco","year":"2011","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib122","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1034\/j.1399-0012.2000.140206.x","article-title":"Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients","volume":"14","author":"Sarmiento","year":"2000","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib123","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/ctr.12708","article-title":"Selection and use of immunosuppressive therapies after liver transplantation: current German practice","volume":"30","author":"Herzer","year":"2016","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib124","first-page":"361","article-title":"Use of everolimus-based immunosuppression to decrease cytomegalovirus infection after kidney transplant","volume":"14","author":"Malvezzi","year":"2016","journal-title":"Exp Clin Transplant"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib125","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib126","doi-asserted-by":"crossref","first-page":"45","DOI":"10.7326\/0003-4819-118-1-199301010-00009","article-title":"NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management","volume":"118","author":"Straus","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bpg.2020.101689_bib127","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/TP.0b013e3181b7509c","article-title":"Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new out- looks","volume":"88","author":"Abu-Elmagd","year":"2009","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib128","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOT.0b013e3283465715","article-title":"Posttransplant lymphoproliferative disease following liver transplantation","volume":"16","author":"Kamdar","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"issue":"10","key":"10.1016\/j.bpg.2020.101689_bib129","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.meg.0000231752.50587.ae","article-title":"Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?","volume":"18","author":"Burra","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib130","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1600-6143.2011.03893.x","article-title":"Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States","volume":"12","author":"Dharnidharka","year":"2012","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib131","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2141.2010.08161.x","article-title":"Haemato-oncology task force of the British committee for standards in haematology and British transplantation society. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib132","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1600-6143.2008.02183.x","article-title":"EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial","volume":"8","author":"Tsai","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2020.101689_bib133","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"8","key":"10.1016\/j.bpg.2020.101689_bib134","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00007890-200210270-00007","article-title":"Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome","volume":"74","author":"Dotti","year":"2002","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib135","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/lt.21152","article-title":"Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus","volume":"13","author":"Koch","year":"2007","journal-title":"Liver Transplant"},{"issue":"Suppl 4","key":"10.1016\/j.bpg.2020.101689_bib136","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/ajt.12104","article-title":"Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation","volume":"13","author":"Allen","year":"2013","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib137","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib138","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/2040620711412417","article-title":"Therapeutic options in post-transplant lymphoproliferative disorders","volume":"2","author":"Zimmermann","year":"2011","journal-title":"Ther Adv Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2020.101689_bib139","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/343739","article-title":"Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review","volume":"186","author":"Smith","year":"2002","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.bpg.2020.101689_bib140","series-title":"Mandell, douglas, and bennett\u2019s principles and practice of infectious diseases","first-page":"1762","article-title":"Herpes simplex virus","author":"Corey","year":"2005"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib141","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/infdis\/158.1.124","article-title":"Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies","volume":"158","author":"Singh","year":"1988","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.bpg.2020.101689_bib142","series-title":"Transplant infections","first-page":"350","article-title":"Herpes simplex virus and varicella-zoster virus infections in hematopoietic stem cell or solid organ transplantation","author":"Gnann","year":"2003"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib143","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00005792-198803000-00006","article-title":"Infections after liver transplantation. An analysis of 101 consecutive cases","volume":"67","author":"Kusne","year":"1988","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib144","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.10.1.86","article-title":"Infections in solid-organ transplant recipients","volume":"10","author":"Patel","year":"1997","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib145","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/0003-4819-102-6-783","article-title":"Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients","volume":"102","author":"Shepp","year":"1985","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.bpg.2020.101689_bib146","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","article-title":"Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans","volume":"39","author":"Soul-Lawton","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 4","key":"10.1016\/j.bpg.2020.101689_bib147","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ajt.12105","article-title":"Herpes simplex virus in solid organ transplantation","volume":"13","author":"Wilck","year":"2013","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib148","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/tid.12425","article-title":"Incidence and risk factors for herpes zoster in patients undergoing liver transplantation","volume":"17","author":"Hamaguchi","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"10.1016\/j.bpg.2020.101689_bib149","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/lt.20219","article-title":"Herpes zoster after liver transplantation: incidence, risk factors, and complications","volume":"10","author":"Herrero","year":"2004","journal-title":"Liver Transplant"},{"issue":"Suppl 4","key":"10.1016\/j.bpg.2020.101689_bib150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/ajt.12107","article-title":"Varicella zoster virus in solid organ transplantation","volume":"13","author":"Pergam","year":"2013","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib151","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00705-013-1902-5","article-title":"Classification of HHV-6A and HHV-6B as distinct viruses","volume":"159","author":"Ablashi","year":"2014","journal-title":"Arch Virol"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib152","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/CMR.18.1.217-245.2005","article-title":"Update on human herpesvirus 6 biology, clinical features, and therapy","volume":"18","author":"De Bolle","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"Pt 6","key":"10.1016\/j.bpg.2020.101689_bib153","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1099\/0022-1317-72-6-1401","article-title":"Latent human herpesvirus 6 infection of human monocytes\/macrophages","volume":"72","author":"Kondo","year":"1991","journal-title":"J\u00a0Gen Virol"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib154","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jmv.20760","article-title":"The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors","volume":"79","author":"Leong","year":"2007","journal-title":"J\u00a0Med Virol"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1034\/j.1399-3046.2003.00028.x","article-title":"Prevalence and clinical significance of human herpesviruses 6 and 7 active infection in pediatric liver transplant patients","volume":"7","author":"Feldstein","year":"2003","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bpg.2020.101689_bib156","series-title":"Human herpesviruses: biology, therapy, and immunoprophylaxis","article-title":"HHV-6A, 6B, and 7: persistence in the population, epidemiology and transmission","author":"Emery","year":"2007"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib157","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/514592","article-title":"Human herpesvirus-6 infection after liver transplantation","volume":"26","author":"Lautenschlager","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.bpg.2020.101689_bib158","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1097\/00007890-200006270-00015","article-title":"Human herpesvirus-6 antigenemia after liver transplantation","volume":"69","author":"Lautenschlager","year":"2000","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib159","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/lt.21304","article-title":"Human herpesvirus 6 infection in adult living related liver transplant recipients","volume":"14","author":"Ohashi","year":"2008","journal-title":"Liver Transplant"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00007890-200202270-00021","article-title":"Clinical impact of human herpesvirus 6 infection after liver transplantation","volume":"73","author":"Humar","year":"2002","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib161","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMoa074479","article-title":"HHV-6A in syncytial giant-cell hepatitis","volume":"359","author":"Potenza","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2020.101689_bib162","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2011.12.017","article-title":"High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis","volume":"56","author":"Pischke","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2020.101689_bib163","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcv.2011.02.001","article-title":"Detection of HHV-6 in over a thousand samples: new types of infection revealed by an analysis of positive results","volume":"51","author":"Revest","year":"2011","journal-title":"J\u00a0Clin Virol"},{"issue":"6","key":"10.1016\/j.bpg.2020.101689_bib164","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/jmv.20626","article-title":"HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation","volume":"78","author":"H\u00e4rm\u00e4","year":"2006","journal-title":"J\u00a0Med Virol"},{"issue":"8","key":"10.1016\/j.bpg.2020.101689_bib165","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.transproceed.2012.07.034","article-title":"Co-infection and clinical impact of human herpesvirus 5 and 6 in liver transplantation","volume":"44","author":"Sampaio","year":"2012","journal-title":"Transplant Proc"},{"issue":"12","key":"10.1016\/j.bpg.2020.101689_bib166","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1097\/00007890-200006270-00016","article-title":"Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome","volume":"69","author":"Rogers","year":"2000","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib167","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bjid.2013.07.007","article-title":"Human herpesvirus-6 and cytomegalovirus DNA in liver donor biopsies and their correlation with HLA matches and acute cellular rejection","volume":"18","author":"Guardia","year":"2014","journal-title":"Braz J Infect Dis"},{"issue":"3","key":"10.1016\/j.bpg.2020.101689_bib168","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1309\/AJCP0FWI2XAHECBJ","article-title":"Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients","volume":"140","author":"Buyse","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.bpg.2020.101689_bib169","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000066172","article-title":"Encephalitis caused by human herpesvirus-6 in a liver transplant recipient","volume":"48","author":"Montejo","year":"2002","journal-title":"Eur Neurol"},{"key":"10.1016\/j.bpg.2020.101689_bib170","series-title":"Human herpesviruses HHV-6A, HHV-6B & HHV-7: diagnosis and clinical management","first-page":"311-320","article-title":"Treating HHV-6 infections","author":"Pritchett","year":"2014"},{"issue":"2","key":"10.1016\/j.bpg.2020.101689_bib171","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/liv.13506","article-title":"HHV-6 in liver transplantation: a literature review","volume":"38","author":"Phan","year":"2018","journal-title":"Liver Int"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169182030024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169182030024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:02:12Z","timestamp":1761498132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169182030024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":171,"alternative-id":["S152169182030024X"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2020.101689","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post liver transplant recurrent and de novo viral infections","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2020.101689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101689"}}